MedTrace Logo

Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis

NCT00769587 · Status: COMPLETED · Type: INTERVENTIONAL

Last updated 2025-09-22

No results posted yet for this study

Summary

RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease.

PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive systemic mastocytosis.

Conditions

  • Non Neoplastic Condition
  • Precancerous Condition

Interventions

DRUG

thalidomide

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Principal Investigators

  • Gandhi Damaj · Centre Hospitalier Universitaire, Amiens

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2011-05-31
Completion
2012-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00769587 on ClinicalTrials.gov